Found vs Telos Rx
Two GLP-1 desks, one scoreboard. We put Found and Telos Rx head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
The verdict
Found takes this head-to-head.
Found scores 88 to 85 on our six-factor Brief Score — A coaching-first program with the lowest identical price on both molecules — if you want the coaching lock-in that comes with it.
That doesn't make Telos Rx a bad call — it's best for readers who want glp-1 care and a needle-free oral or microdosed route on the same certified desk that also carries peptides, nad+ and hrt — and will trade fda-approved brand access and up-front pricing for the deepest menu at the lowest annual-lock rate. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Found | Telos Rx | |
|---|---|---|
| Brief Score | 88/100 (B+) | 85/100 (B) |
| Semaglutide | $129/mo | $49/mo (microdosed, annual) |
| Tirzepatide | $129/mo | $99/mo (annual) |
| Coverage | All 50 states | Not publicly listed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
Found: Lowest identical-price line on the board — but bundled into a coaching subscription.
Telos Rx: Headline GLP tiers held flat this cycle, but the $49 microdosed and $99 tirzepatide rates are annual-lock prices — short-term plans run meaningfully higher, and everything outside GLP-1 stays unpriced until intake.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.